Idenix to Host Conference Call Discussing Second Quarter and Six Month 2011 Financial Results

CAMBRIDGE, Mass., July 21, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc., (NASDAQ: IDIX) announced today that it will report its financial results for the second quarter of 2011 on Monday, August 8, 2011 after U.S. financial markets close.

Idenix management will host a conference call at 4:30 p.m. ET on Monday, August 8, 2011 to discuss the company's financial results for the second quarter of 2011 and provide an update on the company's development programs.

To access the call please dial (800) 471-3635 U.S./Canada or (706) 758-9475 International and enter passcode 86055177. There will also be a slide presentation available to accompany the conference call, which can be accessed shortly before the start of the conference call on our website in the Idenix Investor Center at www.idenix.com.  To listen to a live webcast of the call, go to “Calendar of Events” in the Idenix Investor Center at www.idenix.com. Please log in approximately 10 minutes before the call to ensure a timely connection. A replay of the conference call and webcast will be available until August 22, 2011. To access the replay, please dial (800) 642-1687 U.S./Canada or (706) 645-9291 International and enter the passcode 86055177.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)

SOURCE Idenix Pharmaceuticals, Inc.

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.